Powder: -20°C for 3 years | In solvent: -80°C for 1 year
XVA143, an α/β I-like allosteric antagonist, inhibits LFA-1 dependent firm adhesion, while at the same time it enhances adhesion in shear flow and rolling both in vitro and in vivo. XVA143 is an antagonist of both mouse and human CR3, inhibits the ability of P. gingivalis to persist in the mouse host and cause periodontal bone loss.
产品描述 | XVA143, an α/β I-like allosteric antagonist, effectively blocks LFA-1 dependent firm adhesion but simultaneously increases adhesion under shear flow and rolling conditions, both in vitro and in vivo. |
体外活性 |
XVA143 (1 μM) completely abolishes binding of ICAM-1 to LFA-1 in Mn 2+ and Mg 2+ /EGTA, with no hint of agonism[1].
XVA143 restores rolling of the α L -E310A β 2 mutant by inducing extension of α L[2]. Cell Viability Assay[1]Cell Line: K562 cells. Concentration: 0, 0.2, 0.5 and 1 μM. Incubation Time: Result: Potent against the weakest activator (2 mM Mg 2+ /1 mM EGTA, IC 50 ~10 -3 nM) and least potent against the strongest activator (1 mM Mn 2+ , IC 50 ~10 -3 nM). Cell Viability Assay[1]Cell Line: Wild-type murine lymphocytes[1]. Concentration: 100 μM. Incubation Time: Result: Induced a 50% increase in rolling fraction compared to vehicle-treated control cells ((from 27±5% to 41±7%). |
别名 | XVA143 |
分子量 | 562.36 |
分子式 | C25H21Cl2N3O8 |
CAS No. | 264275-77-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
XVA143 264275-77-6 XVA-143 XVA 143 Inhibitor inhibitor inhibit